Physician profile
William E Basri
NPI 1992778948
$13,048.52
in general payments reported to CMS, 2019-2025
37 companies · $2,377 in 2025
The $2,377 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,369 · 2020: $1,182 · 2021: $2,115 · 2022: $2,036 · 2023: $1,927 · 2024: $2,044 · 2025: $2,377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,063 · Education: $245 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,062.90 |
| Education | $244.81 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,881.86 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Abbvie INC. | $2,275.26 | 2019-2025 | Skyrizi, Linzess, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,145.13 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Celgene Corporation | $709.91 | 2021-2024 | Zeposia |
| Pfizer INC. | $653.79 | 2019-2025 | |
| Madrigal Pharmaceuticals | $608.00 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $532.12 | 2019-2025 | |
| Genzyme Corporation | $501.78 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $379.30 | 2019-2024 | Entyvio, Eohilia, Gattex |
| Redhill Biopharma INC. | $326.30 | 2020-2024 | Talicia, Aemcolo, Movantik |
| Qol Medical, LLC | $321.18 | 2019-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $235.19 | 2024-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $185.25 | 2019-2023 | Dificid |
| Regeneron Healthcare Solutions, INC. | $163.66 | 2023-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $129.52 | 2024-2025 | Voquezna |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $114.80 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $91.02 | 2020-2023 | Linzess |
| Hologic Sales and Service, LLC | $90.91 | 2024 | Coolseal Generator |
| Ferring Pharmaceuticals INC. | $89.29 | 2019-2023 | Rebyota, Cimzia |
| Ardelyx, INC. | $82.59 | 2023-2024 | Ibsrela |
| Evoke Pharma, INC. | $75.08 | 2021-2022 | |
| Medtronic, INC. | $73.95 | 2021-2022 | |
| Lucid Diagnostics INC. | $66.00 | 2022 | |
| Romark Laboratories, Lc | $54.22 | 2019-2020 | |
| Braintree Laboratories, INC. | $52.75 | 2020-2022 | |
| Davol INC. | $40.00 | 2024 | Phasix Mesh |
| Celltrion USA INC. | $35.74 | 2025 | Vegzelma |
| Alfasigma USA, INC. | $24.51 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $19.61 | 2025 | Iqirvo |
| Blueprint Medicines Corporation | $17.12 | 2022 | |
| Exact Sciences Corporation | $16.42 | 2025 | Cologuard Collection Kit |
| Organon LLC | $14.90 | 2023 | Renflexis |
| Vivus LLC | $14.37 | 2019 | |
| Janssen Scientific Affairs, LLC | $14.20 | 2025 | Tremfya |
| Intercept Pharmaceuticals, INC. | $12.79 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Basri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.